Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphoma, Non-Hodgkin: early-phase trial registry
16 of 62 indexed Lymphoma, Non-Hodgkin trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #228 of 28,707 conditions by registered trial count.
62 US clinical trials · 16 currently recruiting · #228 of 28,707 conditions by registered trial count
Lymphoma, Non-Hodgkin: 62 US clinical trials tracked, 16 recruiting.
Lymphoma, Non-Hodgkin is the subject of 62 registered US clinical trials on ClinicalTrials.gov, 16 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 44 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.
Enrollment posture brief
Registry condition lymphoma-non-hodgkin
OPEN 16 | RECR 26% | LATE 5 | EARLY 44 | RANK #228 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Diabetic Retinopathy (26% recruiting · 58 trials)
Lymphoma, Non-Hodgkin lists 16 open slots (26% of 62 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphoma, Non-Hodgkin on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphoma, Non-Hodgkin is recruiting below its size-band peers.
16 of 62 indexed trials (25.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lymphoma, Non-Hodgkin trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 5 of 62 trials (8.1%). 45 distinct sponsors appear on at least one study for this condition label.
-
Typical Lymphoma, Non-Hodgkin enrolment sits around 67 participants.
Median target enrolment is 67 among the 59 trials that report a genuine target (sentinel values excluded). 33 of those (55.9%) plan for fewer than 100 participants.
-
Lymphoma, Non-Hodgkin research is mostly interventional.
54 interventional and 8 observational studies make up this index (87.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
62 total, page 2 of 2
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
Seagen
NCT00655837
Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)
Oncology Specialists, S.C.
NCT00156013
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000801
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
Triphase Research and Development III
NCT03682796
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma
Dana-Farber Cancer Institute
NCT00117156
A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines
National Cancer Institute (NCI)
NCT00001571
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Celgene
NCT04434196
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
Sherif S. Far
NCT01720264
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
Biogen
NCT00168727
Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
University of California, San Francisco
NCT02187133
A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant
Glaxo Wellcome
NCT00002284
Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.
Chiron Corporation
NCT00045864
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 30 |
| Phase 2 | 14 |
| Phase 3 | 3 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Lymphoma, Non-Hodgkin records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphoma, Non-Hodgkin trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphoma, Non-Hodgkin page
62 registered trials, 16 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 16 Lymphoma, Non-Hodgkin trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Lymphoma, Non-Hodgkin trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoma, Non-Hodgkin condition card totals 62 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.